Analyst Reco. Merck & Co., Inc.

Stocks

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 08:14:12 18/06/2026 pm IST			5-day change	1st Jan Change
112.60 ^USD	-2.46%		-6.89%	+6.82%

05:36pm	Merck Receives U.S. FDA Approval for Expanded Indication of CAPVAXIVE Pneumococcal 21-Valent Conjugate Vaccine in Children and Adolescents Aged 2 Through 17 At Increased Risk for Pneumococcal Disease	CI
04:52pm	Merck Says FDA Approved Capvaxive in High-Risk Pediatric Patients	MT

Analyst Reco.

18/05	Regeneron drops after skin cancer treatment fails late-stage trial	RE
01/05	Goldman Sachs Adjusts Merck Price Target to $137 From $133	MT
01/05	Wells Fargo Adjusts Merck Price Target to $145 From $150	MT
01/05	Morgan Stanley Raises Price Target on Merck to $112 From $109, Keeps Equalweight Rating	MT
21/04	Arcus Biosciences Has Favorable Setup After Merck Belzutifan Failure, Wedbush Says	MT
21/04	Leerink Partners Cuts Merck Price Target to $127 From $129, Maintains Outperform Rating	MT
08/04	Wolfe Research Adjusts PT on Merck & Co. to $150 From $142, Maintains Outperform Rating	MT
06/04	JPMorgan Adjusts Price Target on Merck & Co. to $135 From $125, Maintains Overweight Rating	MT
31/03	Jefferies Adjusts Price Target on Merck & Co. to $138 From $132, Maintains Buy Rating	MT
19/03	Citigroup Adjusts Price Target on Merck & Co. to $125 From $120, Maintains Neutral Rating	MT
19/03	Jefferies Adjusts Price Target on Merck & Co. to $132 From $130, Maintains Buy Rating	MT
12/03	Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating	MT
03/03	Wolfe Adjusts Price Target on Merck to $142 From $135, Maintains Outperform Rating	MT
02/03	Leerink Partners Adjusts Price Target on Merck & Co to $129 From $128, Maintains Outperform Rating	MT
20/02	HSBC Adjusts Price Target on Merck to $135 From $120, Maintains Buy Rating	MT
20/02	Barclays Initiates Coverage on Merck With Overweight Rating	MT
14/02	Merck Shares Rise After Deutsche Bank Upgrade	MT
13/02	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
13/02	Deutsche Bank Upgrades Merck to Buy From Hold, Adjusts Price Target to $150 From $115	MT
12/02	Argus Adjusts Price Target on Merck to $130 From $110, Maintains Buy Rating	MT
11/02	Daiwa Securities Adjusts PT on Merck & Co. to $120 From $86, Maintains Neutral Rating	MT
10/02	Rothschild & Co Redburn Adjusts Price Target on Merck & Co. to $140 From $135, Maintains Buy Rating	MT
06/02	Guggenheim Adjusts Price Target on Merck & Co to $140 From $122, Maintains Buy Rating	MT
04/02	Merck's Pipeline Progress and Business Development Strategy Remain in Focus, Morgan Stanley Says	MT
04/02	Bernstein Adjusts Price Target on Merck to $100 From $95, Maintains Market Perform Rating	MT